日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan

针对既往接受过治疗且伴有腹膜播散的胃癌患者,采用溶剂型或白蛋白结合型紫杉醇联合雷莫芦单抗治疗,并进行预先设定的生物标志物分析(P-SELECT/WJOG10617G):一项在日本开展的随机II期临床试验

Hirata, Kenro; Hamamoto, Yasuo; Shoji, Hirokazu; Hara, Hiroki; Kondoh, Chihiro; Yasui, Hisateru; Kajiwara, Takeshi; Baba, Eishi; Ando, Takayuki; Sugimoto, Naotoshi; Kawakami, Hisato; Katsuya, Hiroo; Nagase, Michitaka; Yamamoto, Yoshiyuki; Yoshimura, Kenichi; Ando, Masahiko; Imamura, Chiyo K; Yamazaki, Kentaro; Hironaka, Shuichi; Muro, Kei

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

雷莫芦单抗治疗进展后联合伊立替康治疗雷莫芦单抗难治性晚期胃癌患者的随机III期试验:RINDBeRG试验

Sakai, Daisuke; Kadowaki, Shigenori; Kawabata, Ryohei; Hara, Hiroki; Satake, Hironaga; Takahashi, Masazumi; Takeno, Atsushi; Imai, Hiroo; Minashi, Keiko; Kawakami, Takeshi; Boku, Shogen; Matsuyama, Jin; Sakamoto, Yasuhiro; Sawada, Kentaro; Kataoka, Masato; Kawakami, Hisato; Shimokawa, Toshio; Boku, Narikazu; Satoh, Taroh

NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

NOTCH1 突变与替利珠单抗治疗晚期或转移性食管鳞状细胞癌的生存分析:来自随机 III 期 RATIONALE-302 试验的生物标志物分析

Lu Zhihao, Du Wenting, Jiao Xi, Wang Yanni, Shi Jingwen, Shi Yang, Shu Yongqian, Niu Zuoxing, Hara Hiroki, Wu Jun, Hsu Chih-Hung, Van Cutsem Eric, Brock Malcolm V, Zhang Zhang, Ding Ningning, Zhang Yun, Shen Zhirong, Shen Lin

Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802).

在无法切除的局部晚期食管鳞状细胞癌患者中,接受根治性放化疗后使用阿特珠单抗治疗——一项多中心 2 期试验 (EPOC1802)

Bando Hideaki, Kumagai Shogo, Kotani Daisuke, Mishima Saori, Irie Takuma, Itahashi Kota, Tanaka Yosuke, Habu Takumi, Fukaya Sayuri, Kondo Masaki, Tsushima Takahiro, Hara Hiroki, Kadowaki Shigenori, Kato Ken, Chin Keisho, Yamaguchi Kensei, Kageyama Shun-Ichiro, Hojo Hidehiro, Nakamura Masaki, Tachibana Hidenobu, Wakabayashi Masashi, Fukui Makoto, Fuse Nozomu, Koyama Shohei, Mano Hiroyuki, Nishikawa Hiroyoshi, Shitara Kohei, Yoshino Takayuki, Kojima Takashi

Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study

Tasurgratinib治疗胆管癌或胃癌患者:首次人体I期研究的扩展部分

Morizane, Chigusa; Ueno, Makoto; Ioka, Tatsuya; Tajika, Masahiro; Ikeda, Masafumi; Yamaguchi, Kensei; Hara, Hiroki; Yabusaki, Hiroshi; Miyamoto, Atsushi; Iwasa, Satoru; Muto, Manabu; Takashima, Tsutomu; Minashi, Keiko; Komatsu, Yoshito; Nishina, Tomohiro; Nakajima, Takako Eguchi; Takeno, Atsuchi; Moriwaki, Toshikazu; Furukawa, Masayuki; Sahara, Takatoshi; Ikezawa, Hiroki; Nomoto, Maiko; Takashima, Shuya; Uehara, Taisuke; Funasaka, Setsuo; Yashiro, Masakazu; Furuse, Junji

ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer

ONO-4578联合纳武利尤单抗治疗不可切除的晚期或复发性胃癌或胃食管交界处癌

Kawazoe, Akihito; Yamaguchi, Kensei; Hamaguchi, Tetsuya; Narita, Yukiya; Boku, Shogen; Oshima, Takashi; Hara, Hiroki; Hamamoto, Yasuo; Ishido, Kenji; Esaki, Taito; Hosaka, Hisashi; Yasui, Hirofumi; Koeda, Keisuke; Nishina, Tomohiro; Tsuji, Yasushi; Fukagawa, Takeo; Goto, Masahiro; Oki, Eiji; Sugimoto, Naotoshi; Matsuoka, Hiroshi; Yokoyama, Fumiharu; Yoshida, Tomoko; Yoshida, Kazuo; Oshima, Yoshiaki; Iwasa, Satoru

Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High)

循环肿瘤DNA在HER2阳性晚期胃癌中的临床意义:一项双重HER2和PD-1靶向治疗Ib期试验的合作研究(Ni-High)

Osumi, Hiroki; Wakatsuki, Takeru; Ooki, Akira; Chin, Keisho; Shoji, Hirokazu; Ogura, Mariko; Nakayama, Izuma; Yamamoto, Noriko; Hirano, Hidekazu; Hara, Hiroki; Minashi, Keiko; Shinozaki, Eiji; Kato, Ken; Ishizuka, Naoki; Kitano, Shigehisa; Takeuchi, Kengo; Boku, Narikazu; Yamaguchi, Kensei; Takahari, Daisuke

Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1-Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

纳武利尤单抗单药治疗PD-1阳性CD8/Treg比值高的晚期非小细胞肺癌和胃癌患者的疗效和安全性:一项II期多中心研究

Shitara, Kohei; Tamiya, Motohiro; Okishio, Kyoichi; Hosaka, Hisashi; Shinozaki, Katsunori; Seki, Nobuhiko; Hara, Hiroki; Narita, Yukiya; Shiraishi, Takeshi; Tamura, Yosuke; Tsuji, Akihito; Tsuji, Kunihiro; Watanabe, Naohiro; Tanaka, Hiroshi; Yamaguchi, Toshifumi; Yamaguchi, Kensei; Izumi, Hiroki; Ushida, Yasunori; Suna, Hideaki

Impact of time from diagnosis to endoscopic submucosal dissection on curability in superficial esophageal squamous cell carcinoma

从诊断到内镜黏膜下剥离术的时间对浅表食管鳞状细胞癌治愈率的影响

Sato, Daiki; Sasabe, Maasa; Mitsui, Tomohiro; Furue, Yasuaki; Yoshii, Takako; Hara, Hiroki; Oka, DaiJi; Fukuda, Takashi; Yoda, Yusuke

The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

SCRUM-MONSTAR癌症组学生态系统:力求在精准医学领域实现质的飞跃

Hashimoto, Tadayoshi; Nakamura, Yoshiaki; Fujisawa, Takao; Imai, Mitsuho; Shibuki, Taro; Iida, Naoko; Ozaki, Hiroshi; Nonomura, Norio; Morizane, Chigusa; Iwata, Hiroji; Okano, Susumu; Yamagami, Wataru; Yamazaki, Naoya; Kadowaki, Shigenori; Taniguchi, Hiroya; Ueno, Makoto; Boku, Shogen; Oki, Eiji; Komatsu, Yoshito; Yuki, Satoshi; Makiyama, Akitaka; Otsuka, Tomoyuki; Hara, Hiroki; Okano, Naohiro; Nishina, Tomohiro; Sakamoto, Yasutoshi; Miki, Izumi; Kobayashi, Shin; Yuda, Junichiro; Kageyama, Shun-Ichiro; Nagamine, Michiko; Sakashita, Shingo; Sakamoto, Naoya; Yamashita, Riu; Koga, Yoshikatsu; Bando, Hideaki; Ishii, Genichiro; Kuwata, Takeshi; Park, Woong-Yang; Ohtsu, Atsushi; Yoshino, Takayuki